Biotech · Private company
Gamida Cell ltd
Track this companyFree. Adds Gamida Cell ltd to your Dealase workspace and tells you when its record changes.
Clinical trials102 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- Cord Blood UnitPhase 3 · Hematological MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- NiCord® (omidubicel)Phase 3 · Hematological MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- omidubicelPhase 3 · Hematological MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- CordInPhase 2 · Sickle Cell DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- GDA-201Phase 2 · Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- NiCordPhase 2 · Sickle Cell Disease & ThalassemiaClinicalTrials.gov · fetched Nov 12, 2026
- NiCord®Phase 2 · Acute Lymphoblastic Leukemia (ALL)ClinicalTrials.gov · fetched Nov 12, 2026
- NiCord®Phase 2 · Hematological MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
- NiCord®/CordIn™ (omidubicel)Patients Transplanted With NiCord/CordIn (Omidubicel)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- Motixafortide for MRD Sensitization in AMLPHASE2 · RECRUITING · started Jul 23, 2026ClinicalTrials.gov NCT07392970 · fetched Nov 12, 2026
- Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE TrialPHASE4 · RECRUITING · started Sep 24, 2025ClinicalTrials.gov NCT07101445 · fetched Nov 12, 2026
- Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHLPHASE1_PHASE2 · TERMINATED · started Jul 5, 2022ClinicalTrials.gov NCT05296525 · fetched Nov 12, 2026
- Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological MalignanciesPHASE3 · COMPLETED · started Jul 8, 2020ClinicalTrials.gov NCT04260698 · fetched Nov 12, 2026
- Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDSPHASE3 · COMPLETED · started Dec 16, 2016ClinicalTrials.gov NCT02730299 · fetched Nov 12, 2026
- Allogeneic SCT of CordIn™, in Patients With HemoglobinopathiesPHASE1_PHASE2 · TERMINATED · started Apr 4, 2016ClinicalTrials.gov NCT02504619 · fetched Nov 12, 2026
- Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) PatientsCOMPLETED · started May 1, 2014ClinicalTrials.gov NCT02039557 · fetched Nov 12, 2026
- Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HMPHASE1_PHASE2 · COMPLETED · started Apr 1, 2013ClinicalTrials.gov NCT01816230 · fetched Nov 12, 2026
- Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With HemoglobinopathiesPHASE1_PHASE2 · COMPLETED · started Sep 1, 2012ClinicalTrials.gov NCT01590628 · fetched Nov 12, 2026
- Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological MalignanciesPHASE1_PHASE2 · COMPLETED · started Nov 1, 2010ClinicalTrials.gov NCT01221857 · fetched Nov 12, 2026